Autolus Therapeutics to Report First Quarter 2023 Financial Results and Host Conference Call on May 4, 2023
20. April 2023 07:00 ET
|
Autolus Therapeutics plc
LONDON, April 20, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics Announces Publication in Molecular Therapy
04. April 2023 07:00 ET
|
Autolus Therapeutics plc
- Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR - AUTO1/22 may reduce CD19 negative escape in children with B-ALL, and may have broader applications in...
Autolus Therapeutics announces resignation of Chief Financial Officer
14. März 2023 07:00 ET
|
Autolus Therapeutics plc
- Dr. Lucinda Crabtree to step down with effect from Q3 2023 – - Search for new CFO has been initiated - LONDON, March 14, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a...
Autolus Therapeutics Has No Business Relationship with Silicon Valley Bank
13. März 2023 07:00 ET
|
Autolus Therapeutics plc
LONDON, March 13, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today and...
Autolus Therapeutics Reports Full Year 2022 Financial Results and Operational Progress
07. März 2023 07:00 ET
|
Autolus Therapeutics plc
Obe-cel, a potentially transformational treatment for relapsed/refractory (r/r) B-cell Acute Lymphoblastic Leukemia (ALL) met the primary endpoint in the pivotal Phase 2 FELIX study and is on track...
Autolus Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on March 7, 2023
15. Februar 2023 07:00 ET
|
Autolus Therapeutics plc
LONDON, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics announces Board changes
20. Januar 2023 07:00 ET
|
Autolus Therapeutics plc
LONDON, Jan. 20, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announces two...
Autolus Therapeutics Announces Collaboration with Cabaletta Bio for Use of Autolus’ Safety Switch System in Cell Therapies for Autoimmune Disease
09. Januar 2023 07:00 ET
|
Autolus Therapeutics plc
LONDON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces...
Autolus Announces Partial Exercise of Underwriters' Option to Purchase Additional ADSs
21. Dezember 2022 16:01 ET
|
Autolus Therapeutics plc
LONDON, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced today...
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2022
12. Dezember 2022 10:00 ET
|
Autolus Therapeutics plc
Obe-cel: 35% of relapsed/refractory adult B-ALL patients in the ALLCAR19 trial remain in complete remission at a median follow up of three years without the need for additional anti-leukemia...